Yossi Maimon

Protalix BioTherapeutics, Inc.

VP, Chief Financial Officer

Avg. Two Year Performance

(14%) Avg. Purchase Return (7%) Compound

27% Avg. Sale Return 13% Compound

Holdings: 195.0K shares

Last Three Months: 23-Aug-24 -- 22-Nov-24

0 Net Amount

Buy:	0	--
Sell:	0	--

Sentiment

Company Sentiment

Biotechnology

Drugs

Two Year Chart

23-Nov-22 -- 22-Nov-24

Price ($)

Two Year Stock Price Chart

Sentiment

Company Sentiment

Most Recent Insider Transactions